Alzheimers Disease: Erythrocyte 2,3-diphosphoglycerate Content and Circulating ErythropoietinShow others and affiliations
2019 (English)In: Current Alzheimer Research, ISSN 1567-2050, E-ISSN 1875-5828, Vol. 16, no 9, p. 834-835Article in journal (Refereed) Published
Abstract [en]
Background: Alzheimers Disease (AD) features the accumulation of beta-amyloid in erythrocytes. The subsequent red cell damage may well affect their oxygen-carrying capabilities. 2,3-diphosphoglycerate (2,3-DPG) binds to the hemoglobin thereby promoting oxygen release. It is theorized that 2,3-DPG is reduced in AD and that the resulting hypoxia triggers erythropoietin (EPO) release. Methods amp; Objective: To explore this theory, we analyzed red cell 2,3-DPG content and EPO in AD, mild cognitive impairment, and the control group, subjective cognitive impairment. Results: We studied (i) 2,3-DPG in red cells, and (ii) circulating EPO in AD, and both markers were unaffected by dementia. Disturbances of these oxygen-regulatory pathways do not appear to participate in brain hypoxia in AD.
Place, publisher, year, edition, pages
BENTHAM SCIENCE PUBL LTD , 2019. Vol. 16, no 9, p. 834-835
Keywords [en]
Alzheimer; 2, 3-diphosphoglycerate; erythrocytes; erythropoietin; beta-amyloid; cognitive impairment
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:liu:diva-162087DOI: 10.2174/1567205016666190827120108ISI: 000493721100006PubMedID: 31453787OAI: oai:DiVA.org:liu-162087DiVA, id: diva2:1371319
Note
Funding Agencies|Hultmans stiftelse for forskning och bistand; Konung Gustaf V och Drottning Victorias stiftelse; Hjarnfonden; Margaretha af Ugglas Stiftelse; Stiftelsen for Gamla Tjanarinnor; Gun and Bertil Stohnes stiftelse
2019-11-192019-11-192019-11-19